XML 28 R17.htm IDEA: XBRL DOCUMENT v3.25.3
SEGMENT INFORMATION
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
SEGMENT INFORMATION

NOTE 11 – SEGMENT INFORMATION

 

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly provided to the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is the Company’s CODM. The CODM reviews financial information presented by operating segment in making operating decisions, allocating resources, and evaluating financial performance.

 

The Company conducted the business through two primary operating segments: NanoVibronix and ENvue. NanoVibronix derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its Systems and Nasoenteral tubes and related services. Non-allocated administrative and other expenses are reflected in Corporate.

 

The Company’s chief executive officer is its chief operating decision maker (CODM), who allocates resources to and assesses the performance of each operating segment using information about the operating segment’s loss from operations.

 

Goodwill and Assets

 

   NanoVibronix   ENvue   Corporate   Total 
Balance sheet at September 30, 2025:                    
Goodwill  $-   $38,631   $-   $38,631 
Assets  $2,413   $51,970   $-   $54,383 
                     
Balance sheet at December 31, 2024:                    
Goodwill   -    -    -    - 
Assets  $3,629   $-   $-   $3,629 

 

 

Segment operating results

 

Nine months ended September 30, 2025:  NanoVibronix   ENvue   Corporate   Total 
Revenues  $1,738   $503   $-   $2,241 
Cost of revenues   1,062    656    -    1,718 
Research and development   1,227    496    -    1,723 
Selling and marketing   756    1,122    -    1,878 
General and administrative   1,550    1,379    2,068    4,997 
Total operating loss  $(2,857)  $(3,150)  $(2,068)  $(8,075)

 

Nine months ended September 30, 2024:  NanoVibronix   ENvue   Corporate   Total 
Revenues  $2,114   $          -   $         -   $2,114 
Cost of revenues   889    -    -    889 
Research and development   557    -    -    557 
Selling and marketing   545    -    -    545 
General and administrative   2,335    -    -    2,335 
Total operating loss  $(2,212)  $-   $-   $(2,212)

 

Three months ended September 30, 2025:  NanoVibronix   ENvue   Corporate   Total 
Revenues  $          371   $351   $-   $722 
Cost of revenues   187    346    -    533 
Research and development   44    177    -    221 
Selling and marketing   431    381    -    812 
General and administrative   323    577    503    1,403 
Total operating loss  $(614)  $(1,131)  $(503)  $(2,247)

 

Three months ended September 30, 2024:  NanoVibronix   ENvue   Corporate   Total 
Revenues  $    376   $            -   $          -   $376 
Cost of revenues   243    -    -    243 
Research and development   249    -    -    249 
Selling and marketing   181    -    -    181 
General and administrative   673    -    -    673 
Total operating loss  $(970)  $-   $-   $(970)

 

Geographic Information and Major Customer Data

 

The following is a summary of revenues within geographic areas:

 

   2025   2024   2025   2024 
  

Three Months Ended

September 30,

   Nine Months Ended
September 30,		 
   2025   2024   2025   2024 
United States  $694   $349   $2,133   $2,047 
Europe   8    8    25    8 
Australia/New Zealand   20    7    59    21 
Other   -    12    24    38 
Total  $722   $376   $2,241   $2,114 

 

 

For the three and nine months ended September 30, 2025, the Company generated approximately $219 and $616, respectively, in revenue from its largest customer, representing about 59% and 35% of total revenue for those periods. For the same periods in 2024, the Company’s largest customer accounted for approximately 24% and 38% of total revenue, respectively.